Johnson & Johnson and Protagonist Therapeutics presented Phase 3 results for oral IL-23 receptor antagonist Icotyde (IL-23R blocker) in psoriatic arthritis through the ICONIC-PsA 1 trial. The companies reported that 58% of patients achieved a 20% improvement in disease activity at week 16 versus 41% for placebo, meeting the primary endpoint. J&J said the therapy also improved joint and skin symptoms with no new safety signals in the study population. The program is designed to expand Icotyde beyond its March approval for moderate-to-severe plaque psoriasis into the broader inflammatory disease space where psoriasis and psoriatic arthritis overlap. Analysts highlighted differentiation challenges versus AbbVie’s Skyrizi, noting that efficacy appears closer to a convenience story than an outright potency separation. That framing still has commercial implications if patients prefer oral dosing instead of injection or infusion. The data arrive as the class competition for inflammatory disease continues to tighten around comparative efficacy, dosing convenience, and switching likelihood across real-world patient preferences.